The goal of ACTIV is to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.
The Preclinical Working Group is focused on:
- Establishing a centralized process and repository for harmonizing and sharing methods and evaluating animal models
- Extending access to high-throughput screening facilities, especially in biosafety level 3 (BSL-3) labs
- Increasing access to validated animal models
- Enhancing comparison of approaches to identify informative assays
- Generating a process to assess viral variant effects on vaccines and therapeutics
The Tracking Resistance and Coronavirus Evolution (TRACE) initiative is focused on:
- Monitoring global emergence and circulation of SARS-CoV-2 mutations
- Cross-referencing initial sequence data against database of experimentally or clinically phenotyped mutants
- Characterizing prioritized mutants in vitro through critical-path assays
- Characterizing prioritized mutants in vivo through critical-path assays
- Rapidly sharing activity data with ACTIV and scientific community
The ACTIV Preclinical Working Group, in partnership with the National Heart, Lung, and Blood Institute (NHLBI), hosted an expert-led seminar series on post-acute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID.